Mutations in the human Na-K-2Cl cotransporter (NKCC2) identified in Bartter syndrome type I consistently result in nonfunctional transporters

• Published in: Journal of the American Society of Nephrology 2003-06, Vol.14 (6), p.1419-1426
• Main Authors: STARREMANS, Patrick G. J. F, KERSTEN, Ferry F. J, KNOERS, Nine V. A. M, VAN DEN HEUVEL, Lambertus P. W. J, BINDELS, René J. M
• Format: Article
• Language: English
• Subjects: Animals; Bartter Syndrome - genetics; Bartter Syndrome - metabolism; Biological and medical sciences; Bumetanide - pharmacology; Glycoside Hydrolases - pharmacology; Humans; Immunoblotting; Immunohistochemistry; Kidneys; Medical sciences; Molecular Conformation; Mutation; Nephrology. Urinary tract diseases; Oocytes; Protein Processing, Post-Translational; Sodium - pharmacokinetics; Sodium-Potassium-Chloride Symporters - drug effects; Sodium-Potassium-Chloride Symporters - genetics; Sodium-Potassium-Chloride Symporters - metabolism; Solute Carrier Family 12, Member 1; Urinary system involvement in other diseases. Miscellaneous; Xenopus laevis
• ISSN: 1046-6673; 1533-3450
• DOI: 10.1097/01.ASN.0000064948.39199.A0

Bartter syndrome (BS) is a heterogeneous renal tubular disorder affecting Na-K-Cl reabsorption in the thick ascending limb of Henle's loop. BS type I patients typically present with profound hypokalemia and metabolic alkalosis. The main goal of the present study was to elucidate the functional implications of six homozygous mutations (G193R, A267S, G319R, A508T, del526N, and Y998X) in the bumetanide-sensitive Na-K-2Cl cotransporter (hNKCC2) identified in patients diagnosed with BS type I. To this end, capped RNA (cRNA) of FLAG-tagged hNKCC2 and the corresponding mutants was injected in Xenopus laevis oocytes and transporter activity was measured after 72 h by means of a bumetanide-sensitive (22)Na(+) uptake assay at 30 degrees C. Injection of 25 ng of hNKCC2 cRNA resulted in bumetanide-sensitive (22)Na(+) uptake of 2.5 +/- 0.5 nmol/oocyte per 30 min. Injection of 25 ng of mutant cRNA yielded no significant bumetanide-sensitive (22)Na(+) uptake. Expression of wild-type and mutant transporters was confirmed by immunoblotting, showing significantly less mutant protein compared with wild-type at the same cRNA injection levels. However, when the wild-type cRNA injection level was reduced to obtain a protein expression level equal to that of the mutants, the wild-type still exhibited a significant bumetanide-sensitive (22)Na(+) uptake. Immunocytochemical analysis showed immunopositive staining of hNKCC2 at the plasma membrane for wild-type and all studied mutants. In conclusion, mutations in hNKCC2 identified in type I BS patients, when expressed in Xenopus oocytes, result in a low expression of normally routed but functionally impaired transporters. These results are in line with the hypothesis that the mutations in hNKCC2 are the underlying cause of the clinical abnormalities seen in patients with type I BS.